Incivek
Vertex to acquire Crinetics in deal worth around $10bn
The deal includes an approved treatment for acromegaly and other pipeline candidates
Gilead and NHS England extend collaboration to eliminate hepatitis C by 2025
The blood-borne disease is estimated to affect around 62,600 people in England
UKHSA data reveals a 45% decline in hepatitis C prevalence in England
More than 80,000 people have been treated for the virus by NHS England since 2015
NHS England set to be first in world to eliminate hepatitis C by 2030
Deaths from the virus fell by 35% following an antiviral drugs deal worth almost £1bn
NHS England launches hepatitis C screening scheme to reach 2030 elimination goal
The new scheme could help diagnose up to 80,000 people who do not know they have hepatitis C
Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes
Vertex has released results from its phase 1/2 trial for VX-880, a stem-cell-derived therapy that restores insulin production
Hepatitis (C)an’t wait: taking a de-centralized approach to cure the epidemic
Hepatitis C is a curable disease, so why are so many countries off track to achieve the World Health Organization elimination target? This World Hepatitis Day, we compare several countries’...
Vertex expands further into cell and genetic therapies with a deal worth up to $1.2bn
A new deal will see Vertex harness Arbor Biotechnologies gene-editing technology to enhance its discovery efforts
Vertex to lead development of CRISPR Therapeutics-partnered gene therapy
Amended agreement sees Vertex take control of gene therapy programme
Vertex gains FDA fast track designation for diabetes stem cell therapy
Vertex says VX-880 has potential to restore pancreatic islet cell function, including insulin production, in type 1 diabetes patients
Merck’s appeal to restore hepatitis C patent verdict against Gilead fails
US Supreme Court rejects Merck’s appeal over patent dispute verdict of $2.54bn
Moderna inks R&D agreements with Vertex and Chiesi
Biotech agrees to separate deals for the development of gene-editing and mRNA therapies